Bioglutyd (Bioglutide, sometimes written as BioGlutide) is the name associated with the experimental substance NA-931, developed by Biomed Industries. Although this compound often appears in online discussions about peptides, its manufacturer describes it as a small molecule substance (small molecule) administered orally.
The publicly available materials do not contain an independently confirmed, complete chemical structure that would unequivocally determine whether NA-931 belongs to the traditional class of peptides. The very name resembling the names of peptide drugs does not constitute reliable chemical evidence [1,2].
This does not mean that Bioglutyd has not been the subject of scientific research. Conference reports describing preclinical experiments and early human studies are available, as well as entries in clinical trial registries.
The problem lies in the fact that short conference abstracts and manufacturer’s communications do not provide the detailed methodological information and independent confirmation that are expected from a well-documented clinical program.
The article discusses the identity of Bioglutide, its chemical classification, proposed receptor mechanisms, results of animal and clinical studies, and the most important limitations of the available evidence.
What is Bioglutyd? Names, synonyms and identity of the substance
Bioglutyd is the name used by Biomed Industries for the experimental substance designated with the code NA-931.
The following terms appear in the materials related to the development program:
- Bioglutide;
- BioGlutide;
- NA-931.
The manufacturer directly links the name Bioglutide to the code NA-931 [1].
This confirms the naming relationship within the research program, but does not imply independent confirmation of the composition of all products sold under these names.
Why does the name of the substance not suffice to confirm its identity?
The development name allows publications, communications, and clinical studies to be identified.
However, it does not provide an equivalent of a full chemical profile.
In the case of substances whose structure has not been sufficiently disclosed, the named research program must be clearly distinguished from the analytically confirmed molecule.
To link NA-931 with a sample from an independent source, reliable structural and analytical data would be needed.
The mere similarity of the name, the presence of a chromatographic peak, or the declared percentage purity are not sufficient to demonstrate equivalence.
Why do different receptor activity descriptions appear in publications?
In a 2024 animal study summary, NA-931 and related compounds were described as agonists of three receptor systems.
In later reports NA-931 was described as an agonist of four receptors [3,4].
This difference should be preserved when describing the history of the research.
However, it does not allow for the determination of whether the molecule has changed, its pharmacological characteristics have been expanded, or only the terminology has been modified.
The most precise approach is therefore to identify Bioglutide as the name assigned by the manufacturer to NA-931, while noting the limitations regarding the independent verification of the molecular structure.
How is Bioglutyd classified? A peptide, a protein or another substance?
The chemical classification should be based on confirmed molecular properties, and not on similarities in names.
In the case of NA-931, the available materials make it possible to conclude that the manufacturer describes it as an experimental low-molecular substance.
Such a term also appears in the summary of the Phase 2 study from 2025 [2,5].
However, based on the analyzed sources, no complete, independently confirmed chemical structure or amino acid sequence has been established.
Is Bioglutyd a peptide?
This cannot be unequivocally confirmed based on the available data.
The manufacturer and the authors of the phase 2 study summary term NA-931 as a small molecule substance.
However, sufficient structural characteristics have not been provided to definitively resolve all classification issues.
The chemical terminology can overlap to some extent. A short peptide can also fall within the broader category of substances with a low molecular weight.
However, this does not mean that NA-931 can be automatically assigned to a specific class of peptides.
Presenting it as a confirmed peptide of multiple hormones or administering an unverified amino acid sequence would go beyond the available evidence.
Does the term „quadruple agonist” mean a mixture of four hormones?
No.
The term „quadruple agonist” refers to the declared pharmacological activity against four receptor systems.
This does not mean that the preparation contains four hormones or four separate ingredients.
Confirmation of such a mechanism would require appropriate receptor studies conducted on a chemically identified substance.
Is Bioglutyd chemically related to GLP-1 drugs?
The similarity in the name does not confirm chemical kinship.
The names of substances, their structures, and mechanisms of action are separate categories of information.
It should therefore not be assumed that Bioglutyd has a structure similar to approved drugs acting on GLP-1 receptors solely because of the similarly-sounding ending of the name.
The molecular structure of Bioglutide – what has been established?
The complete chemical characterization of the substance should enable its differentiation from structural analogues, synthetic byproducts, and degradation products.
In the case of NA-931, available sources confirm the developmental name and the description of the proposed receptor activity.
However, they do not provide sufficient information for independent verification:
- the exact amino acid sequence, if any;
- a complete summary form;
- stereochemistry of the molecule;
- complete molecular structure;
- an authentic analytical model;
- a clearly documented synthetic identity.
Is NA-931 an IGF-1 metabolite?
In the 2024 conference abstract, NA-931 and related compounds NA-932 and NA-933 were described as IGF-1 metabolites [3].
However, this term does not unequivocally identify a specific chemical structure.
On this basis, it cannot be concluded that NA-931 is identical to a specific, previously known IGF-1 metabolite.
Such a conclusion would require a direct, reliable structural assignment.
Why does the lack of a complete structure hinder the interpretation of analytical certificates?
The cleanliness test provides information about the specific property of the sample, which is evaluated using a specific method.
However, this does not automatically confirm the identity of the unknown substance.
If there is no available and reliable reference point for the NA-931 structure, even a precisely calculated percentage purity result does not allow the sample to be independently determined as being compatible with the material used in clinical studies.
Credible identification would require appropriate, mutually complementary analytical methods, an authentic pattern, and the ability to trace the origin of the material.
Is the oral formulation NA-931 equivalent to the powder for injection?
This cannot be assumed.
The development program examined primarily concerns the oral form of NA-931.
The properties of such a formulation depend, among other things, on the excipients, dissolution, stability, and systemic exposure.
Studies on the oral preparation do not confirm the efficacy or safety of the independent materials offered as injection powders.
The route of administration and the properties of the preparation are important for interpreting the results.
Bioglutyd in scientific studies – animal and clinical evidence
Available studies of NA-931 include animal experiments, early human studies, conference presentations, and entries in clinical trial registries.
The results should be considered separately, taking into account the type of study and the level of reporting detail.
Animal experiences can justify biological hypotheses.
The summaries of clinical studies present preliminary observations in humans.
Registers, on the other hand, allow identifying the project, its status, and the selected characteristics of the study.
None of these sources automatically replaces a complete clinical report.
NA-931 studies in animals
In 2024, at the American Diabetes Association conference, a summary was presented regarding experiments on obese mice caused by a diet [3].
NA-931 and two related compounds were studied.
The experiment period lasted 14 days.
What results have been described?
The summary presents changes in body weight and selected metabolic parameters.
However, an important limitation is the way the results are reported.
Because the publication included several related substances, the greatest reported effects cannot be attributed automatically solely to NA-931.
It is necessary to distinguish the results of individual associations.
Do the results of the studies in mice confirm the effectiveness in humans?
No.
Weight reduction in mice does not indicate sustained clinical efficacy in humans.
It also does not confirm the behavior of muscle strength or the safety of long-term use.
An additional limitation is the form of publication.
The conference abstract constitutes the original scientific report, but it usually does not contain as detailed a description of the methods and supplementary analyses as a full experimental publication.
Early studies of Bioglutide in humans
The interpretation of clinical studies requires consideration of the number of participants, the method of allocation to groups, the response to placebo, the analysis methods, and the handling of missing data.
In the case of NA-931, some information is only available in brief summaries.
Therefore, differences between data derived from conference publications and research registries must be preserved.
Study from 2025 – NCT06615700
A randomized, placebo-controlled study linked to the NCT06615700 registry was described in a summary presented at the 2025 ADA conference [4,6].
The treatment period was 28 days.
The researchers presented short-term changes in body weight and observations regarding tolerance.
How many participants were included in the study?
The ClinicalTrials.gov registry lists 74 participants and the status of the study being completed.
The analyzed post did not provide tabular results.
The way the number of people receiving the active substance is described in the conference abstract does not allow for unambiguous reproduction of the allocation of all 74 participants.
A detailed flow chart of the participants’ movements would be needed for a more complete assessment.
What can be inferred from a 28-day observation?
Such a short period allows for the analysis of early changes in body weight and selected reactions of the body.
However, it is not sufficient to assess the long-term safety, the durability of the results, or the complete profile of rare adverse events.
The results should be considered as part of an early clinical program.
Phase 2 study – 13 weeks
In a later conference abstract from the Endocrine Society, a 13-week phase 2 study was described [5].
The publication was published in the supplement of the scientific journal.
It remains a conference summary, not a full clinical report.
What changes in body weight have been described?
In one of the active groups, an average weight reduction of 13.8% was reported.
This is the result presented in a specific research summary.
This does not mean that every participant experienced the same change.
It also does not allow the observer to independently assess the durability of the effect after the observation has ended.
Why does the number of participants vary between sources?
The conference summary indicated 125 participants.
In contrast, the related registry NCT06564753 lists 126 actual participants [5,7].
Without a full report describing the course of the study, it is not possible to clearly explain this difference.
It should not be ignored or an unconfirmed explanation created.
Why are the results of the comparison with placebo subject to caution?
The conference abstract presents a value of 12.4% regarding the difference compared to placebo.
In turn, a September 2026 manufacturer's report describes a weight reduction of 13.8% in the active group and 1.9% in the placebo group.
The difference between these values is 11.9 percentage points [2.5].
It is not necessary to automatically combine this information into a single agreed result.
Details regarding the analytical population and the statistical methods used would be necessary to explain the discrepancies.
Bioglutyd and body composition – do the studies confirm muscle preservation?
Changes in body composition are an important component of the evaluation of substances studied in the context of weight reduction.
However, the terms „lean body mass”, „skeletal muscle mass” and „muscle strength” do not mean the same thing.
What does the DEXA test measure?
DEXA is a method used, among other things, to assess body composition.
The measurement of non-fat body mass includes water and various tissues that do not contain fat.
It is not a direct measure of the actual skeletal muscle mass.
It also does not automatically provide information about strength or physical fitness.
What data on lean body mass were presented for NA-931?
In previous materials, categorical statements appeared suggesting the absence of muscle loss.
However, a September 2026 manufacturer's communication described a decrease in lean body mass measured by DEXA by 1.7% [2].
The manufacturer also noted that a lean body mass is not the same as skeletal muscle mass alone.
These data therefore do not support the claim of total muscle preservation.
Does the activity associated with IGF-1 confirm muscle protection?
No.
The proposed receptor mechanism may provide a rationale for further research.
However, it does not replace direct measurements of tissue and functional changes.
To demonstrate muscle behavior, it would be necessary to include appropriate methods of evaluating body composition, changes in hydration, total body weight loss, and parameters of strength and fitness.
Safety and tolerance of NA-931 in clinical trials
Early clinical summaries contain information regarding the tolerance of the substance.
However, their scope is limited.
Even if the reported events were mostly mild, this does not mean that all significant or rare adverse reactions are excluded.
To make a more complete assessment, it would be necessary to:
- precise definitions of adverse events;
- the number of participants in individual groups;
- information about discontinuing participation in the study;
- laboratory test results;
- exposure time;
- comparison with placebo;
- detailed data regarding the severity of the incidents.
The short message from the manufacturer does not replace the information that was not presented in the full report.
Further clinical development of Bioglutide
In 2026, Biomed Industries reported plans for Phase 3 studies of NA-931 [8].
Among the announced directions of development, there was also a program involving oral semaglutide.
Such announcements document the manufacturer's research intentions.
However, they do not constitute evidence of complete clinical efficacy in phase 3.
Does the announced Phase 3 study mean confirmed efficacy?
No.
The planned study is not the same as a completed and published study.
To assess effectiveness, real results, appropriate statistical analysis, and safety data are needed.
Future projects cannot be presented as already obtained evidence.
What is known about the study combined with tirzepatide?
In the NCT06732245 registration record analyzed regarding studies associated with tirzepatide, the status remained defined as „not yet recruiting,” meaning that recruitment has not yet begun [9].
The planned dates do not confirm that the participants were actually included in the study.
It is therefore necessary to distinguish between the planned schedule and the actual progress of the project.
How does Bioglutyd work? Proposed receptor mechanisms
According to the manufacturer's materials, NA-931 is supposed to exhibit activity against four receptor systems:
- IGF-1;
- GLP-1;
- GIP;
- glucagon.
This is the proposed pharmacological model of the development program [2].
However, it should not be presented as independently confirmed evidence of equal or appropriately balanced activity towards all four receptors.
Why does receptor activity require separate confirmation?
Each declared mechanism constitutes a separate hypothesis that can be investigated.
A reliable pharmacological profile should include, among other things:
- dependence of activity on concentration;
- appropriate experimental controls;
- receptor selectivity;
- repeatability of results;
- exposure measurements;
- studies on the chemically identified substance.
Without such data, the term „quadruple agonist” remains a description of the claimed mechanism.
Does weight loss confirm the activation of all four receptors?
No.
The change in body weight is a clinical result.
It does not allow the individual to determine which receptor was responsible for the observed effect.
It also does not confirm that all the proposed routes involved the substance.
Appropriate pharmacological studies would be needed to reach such a conclusion.
What role does IGF-1 play in the hypothesis of its action?
The IGF-1-related element is used by the manufacturer to justify interest in body composition.
However, it is not possible to go directly from a relationship between a specific pathway in muscle biology and the claim that the tested substance maintains muscle mass.
This would require direct measurements of the relevant tissues and functions.
Does the oral route of administration confirm the mechanism of action?
No.
Oral administration does not automatically determine the amount of unchanged substance that reaches the site of action.
It also does not explain whether the metabolites are involved in the observed effects.
These are pharmacokinetic and pharmacodynamic questions that require separate studies.
Similarly, it is not possible to assume equivalence between different formulations solely on the basis of a common name.
Limitations of scientific evidence regarding Bioglutide
No independently confirmed chemical structure
One of the most important limitations is the lack of a complete, publicly available and independently verified structural characterization of NA-931.
This makes it difficult to classify the materials chemically and to compare materials from different sources.
This gap should not be filled with an alleged amino acid sequence or chemical pattern.
Limited number of full clinical publications
A significant portion of the available results was presented in conference abstracts and manufacturer’s reports.
These sources contain important information, but often do not present all the methodological details.
Among other things, there is a lack of complete data on the populations analysed, cases of discontinuation of participation, the procedures for handling missing results, and all adverse events.
Why the lack of results in PubMed does not mean the absence of research?
In the review of the source materials, searching for the exact name in PubMed did not yield any records.
At the same time, searches in the publishers' sources allowed the researchers to find the appropriate conference abstracts, including material available in PubMed Central.
PubMed, PubMed Central and all the scientific literature do not have the same scope.
Therefore, the lack of matching in one database does not mean that there are no scientific reports.
Discrepancies between sources
The available materials show differences regarding the number of participants, receptor descriptions, and results adjusted for placebo.
These are issues that require explanation in more comprehensive publications.
They do not constitute the basis for independently creating agreed-upon values or formulating unconfirmed allegations.
Short observation time
Early clinical studies involved relatively short periods.
This limits the ability to assess the durability of changes in body weight and long-term safety.
It is also impossible to rule out rare adverse events based solely on small trials.
Lack of reliable direct comparisons
No properly verified study directly comparing NA-931 with other drugs in humans has been presented in the analyzed sources that would confirm its superiority.
Comparisons of results from different studies are limited by differences in populations, observation time, endpoints, and analytical methods.
The results of the studies in mice cannot replace appropriate comparative studies in humans.
Dependence on the manufacturer's materials
A significant part of the information comes from reports related to the development program.
This does not automatically mean that the presented results are incorrect.
However, it points to the need for full reporting, independent verification, and repeatability of results.
Regulatory status NA-931
In a September 2026 communication, the manufacturer described NA-931 as an experimental substance not permitted for commercial use [2].
The presence of development code, a clinical trial number, a patent, or a summary with a DOI number is not equivalent to permission to market a drug.
Similarly, the online offer does not confirm the regulatory status or the quality of the product.
How should the current state of research be interpreted?
The available information justifies the description of the NA-931 research program and the preliminary results.
However, they do not allow for a definitive determination of all chemical properties, the durability of clinical effects, or the full safety profile.
It is therefore most reasonable to treat the results as preliminary, requiring further verification.
Frequently asked questions about Bioglutyd
1. Does Bioglutyd mean a specific substance?
Bioglutyd refers to NA-931 in the manufacturer’s nomenclature system, but the full, independently confirmed structural identity has not been established based on the sources analyzed [1]. This distinction is important when comparing publications with products from independent vendors. A consistent name can identify a development program, but it does not automatically confirm the identity of each material labeled in this way. Reliable identification requires appropriate structural and analytical data.
2. What do the available studies on Bioglutydine confirm?
Available studies confirm that the results of animal experiments and early human studies have been presented in conference abstracts and manufacturer’s materials [3–5]. These reports provide preliminary observations regarding changes in body weight and selected parameters. However, they do not constitute a complete, independently replicated set of evidence of efficacy and safety. More robust conclusions require full methods, detailed results, and independent replication.
3. Is Bioglutyd definitely a peptide?
Such classification has not been unequivocally confirmed. The manufacturer and the summary of the phase 2 study describe NA-931 as a small molecule substance, whereas the full structure has not been independently verified in the analyzed sources [5]. Therefore, it should not be attributed an unconfirmed amino acid sequence. The most precise is the manufacturer’s description, with a clear indication of structural uncertainty.
4. Are Bioglutyd and NA-931 two names for the same research substance?
Yes. Biomed Industries directly links the name Bioglutide to the NA-931 code [1]. This is useful when searching for publications and identifying a clinical program. However, this does not mean that all independently marketed products containing one of these names have the same composition or properties as the material used in the studies. The two names also do not constitute two independent confirmations of efficacy.
5. Does the term „quadruplex agonist” mean a mixture of four peptides?
No. This term describes the declared activity against four receptor systems, not the number of components of the preparation [2]. Based on this, it cannot be determined whether the substance is a peptide, a small molecule compound, or a mixture. Confirmation of activity against individual receptors requires appropriate pharmacological studies on the chemically identified material.
6. Has the amino acid sequence of Bioglutide been determined?
No reliable sequence has been established based on the analyzed sources. Assigning NA-931 to a sequence derived from the vendor’s offer or another substance would lead to an unconfirmed chemical description. Until an appropriate structural characterization is presented, the nomenclature and documented information should be used. Similarity of names does not justify copying the summary pattern or the sequence of another compound.
7. Are there published studies of Bioglutid in humans, or only advertisements?
There are published conference abstracts regarding human studies, including reports presented at the ADA and Endocrine Society conferences [4,5]. These are important sources of primary scientific information. However, their abbreviated form limits the ability to assess methods, study design, and statistical analysis. Therefore, it is necessary to distinguish the existence of preliminary publications from the availability of full clinical reports.
8. Does the presence of publications in PubMed Central mean that there is a full clinical article?
No. PubMed Central provides both full articles and some conference abstracts. The material regarding the Phase 2 study NA-931 was a summary published in the journal supplement [5]. The place of publication does not change the scope of the presented data. Detailed methods, results tables, and appropriate analyses would be needed for a full clinical assessment.
9. Does the lack of search results in PubMed mean that there are no studies available?
No. The individual research databases differ in the scope of indexing. In the reviewed overview, searching for the exact name in PubMed did not yield any records, but relevant abstracts were found in the sources of the publishers. The absence of results in one database does not constitute evidence of a lack of publication in the entire literature. A reliable assessment should also take into account research registries and conference reports.
10. Do studies confirm that Bioglutyd does not cause muscle loss?
No. The available information does not justify such a categorical statement. In a September 2026 manufacturer’s communication, a reduction in lean body mass measured by DEXA was described, while noting that this parameter is not a direct equivalent of skeletal muscle mass [2]. Confirmation of muscle preservation would require more detailed tissue and functional measurements. A change in total body mass does not allow determining muscle strength preservation.
11. Can the results of weight reduction be directly compared with the results of other medications?
This is not reliable without taking into account the differences between the studies. The observation period, the characteristics of the participants, the control group, statistical methods, and the handling of missing data can significantly influence the reported values [2,5]. Additionally, discrepancies exist in the NA-931 materials between some of the estimates. Without full reports and appropriate direct studies, it is not possible to establish a reliable ranking of effectiveness.
12. Does the status of a completed clinical trial mean independent confirmation of the results?
No. The „completed” status indicates the progress of the study, not an independent assessment of its effectiveness. The analyzed entry regarding phase 2 did not provide tabular results despite the completed status [7]. The registry is an important source of information about the study project, but it does not replace a complete report and a critical assessment of the data.
13. Do the planned Phase 3 studies mean that the results of Phase 3 are already available?
No. The announcement of a clinical program does not equate to the end of the study. Communications from the manufacturer in 2026 describe the planned directions for NA-931 development, including the combination study [8]. However, these plans cannot be presented as evidence of efficacy. Conclusions regarding Phase 3 require actual results from the appropriately conducted studies.
14. Do the results of animal studies confirm the safety and efficacy of NA-931 in humans?
No. Animal experiments can provide information about potential mechanisms and justify further studies. However, they do not confirm clinical efficacy or safety in humans. In the case of the summary for NA-931, an additional limitation is the inclusion of several related compounds, which makes it difficult to attribute all results to a single substance [3]. Appropriately reported clinical studies are needed.
15. Does the analysis certificate confirm that the product complies with NA-931?
Not independently. The analytical certificate is valid only if it refers to a properly identified sample, appropriate methods, and a reliable standard. A high percentage purity value does not resolve the uncertainty regarding the chemical identity. It also does not confirm equivalence to the clinical formulation. Appropriate, mutually complementary analytical methods and the ability to trace the origin of the material would be necessary for reliable identification.
16. Do the oral studies of Bioglutide confirm the properties of the injectable preparations?
No. A change in the route of administration or formulation affects the range of required evidence. The manufacturer's clinical program applies to the oral experimental substance, and the equivalence of independent injection preparations has not been confirmed in the analyzed sources [5]. The mere name similarity does not allow for transferring the results regarding exposure, efficacy, and safety between different product forms.
17. What evidence would most increase the credibility of the information about Bioglutyd?
The disclosure and independent confirmation of the chemical structure of NA-931, the provision of the full analytical characterization, and the publication of complete clinical reports would be of the greatest value. It would also be important to independently replicate the results and clarify discrepancies regarding the number of participants and estimates of efficacy. As long as these issues remain unresolved, the available observations should be considered preliminary and not as confirmation of clinical superiority or safety.
Applications
Bioglutyd is the name assigned to the NA-931 research program, whose manufacturer describes the experimental small molecule as having a proposed activity against several receptor systems related to metabolism.
There are conference abstracts, results of early studies, and entries in clinical registries.
However, the available materials do not allow for independent confirmation of the full molecular structure or a clear classification of NA-931 as a traditional peptide.
Preliminary results regarding body weight require further evaluation in full clinical publications.
All questions regarding receptor mechanisms, muscle mass retention, durability of results, and long-term safety have also not been resolved.
Therefore, it is most justified to present a separate document containing the documented research program, the manufacturer’s declaration, and the results requiring independent confirmation.
Educational, medical and regulatory reservations
The article is of purely scientific informational nature and does not constitute medical advice, diagnosis, or recommendations for the purchase or use of Bioglutide (NA-931). The substance remains subject to research, and its full chemical identity has not been independently confirmed in the analyzed sources. The available reports do not establish that NA-931 is an approved, safe, or effective treatment for obesity, diabetes, or other diseases. The results of oral formulation studies do not confirm the properties of independent products marketed under the same name, in particular injectable preparations. Treatment decisions should be based on current regulatory information and consultation with qualified medical personnel.
References
- Medibid Industries. (n.d.). NA-931 [Developer product-program description]. Retrieved October 23, 2026, from https://www.biomedind.com/NA-931.html
- Medibio Industries. (2026, September 26). MedBio Industries presents phase 2 results for oral NA-931 at Obesity Science and Innovation Conference in Boston [Press release]. https://biomedind.com/news-NA-931-OSI.html
- Tran, L. L. (2024). 2059-LB: NA-931, a novel triple IGF-1/GLP-1/GIP incretin receptor agonist, reduces body weight and improves metabolic profile in DIO mice [Conference abstract]. Diabetes, 73(Supplement 1), 2059-LB. https://doi.org/10.2337/db24-2059-LB
- Tran, L. L. (2025). 143-OR: NA-931, a novel quadruple IGF-1-1, GLP-1, GIP, and glucagon receptor agonist reduces body weight without muscle loss [Abstract from conference]. Diabetes, 74(Supplement 1), 143-OR. https://doi.org/10.2337/db25-143-OR
- Tran, L., Vu, F., & Tran, Z. V. (2025). Clinical trials of SAT-713 Phase 2 to study subjects who are obese with at least one weight-related comorbid condition [Abstract from conference]. Journal of the Endocrine Society, 9(Supplement 1), Article bvaf149.144. https://doi.org/10.1210/jendso/bvaf149.144
- Medibio Industries, Inc. (2024). Phase 1: Study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of NA-931 in obese participants and patients with type 2 diabetes mellitus (NCT06615700) [Clinical trial registration]. ClinicalTrials.gov. Retrieved October 23, 2026, from https://clinicaltrials.gov/study/NCT06615700
- Medibid Industries, Inc. (2025). Phase 2 Trials of NA-931 to Study Subjects Who Are Obese With at Least One Weight-related Comorbid Condition (NCT06564753) [Clinical trial registration]. ClinicalTrials.gov. Retrieved October 23, 2026, from https://clinicaltrials.gov/study/NCT06564753
- Medibio Industries. (2026). MedBio Industries presents phase 3 programs of NA-931 alone and in combination with oral semaglutide for obesity at ADA 2026 [Press release]. https://biomedind.com/news-Phase3-NA-931.html
- Medibid Industries, Inc. (2026). Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese (NCT06732245) [Clinical trial registration]. ClinicalTrials.gov. Retrieved October 23, 2026, from https://clinicaltrials.gov/study/NCT06732245